Carlos Fernando Mourão, Gutemberg Gomes Alves
Platelet derivatives have become a central strategy in regenerative medicine due to their capacity to concentrate autologous signals that initiate and coordinate tissue repair. These materials function as transient regulators of the cellular microenvironment, shaping immune-stromal interactions, cell migration, differentiation programs, and extracellular matrix organization. However, terms such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) encompass an ecosystem of preparations with considerable variability in composition, physical form, and biological performance. This heterogeneity, driven by differences in centrifugation parameters, anticoagulants, activation methods, tube types, and patient characteristics, explains inconsistent results across studies and hinders evidence consolidation. This mini-review discusses platelet derivatives along three axes: (i) their biological foundations and functional differences at the cellular and tissue microenvironment level among product families (PRP, PRF, formulations with modified plasma fractions, and human platelet lysate); (ii) how preparation variables impact reproducibility and interpretation of evidence; and (iii) current trends toward standardization, including classification systems, minimum reporting checklists, and dose/potency frameworks such as DEPA (Dose, Efficiency, Purity, Activation). Practical elements for minimum reporting are outlined to reduce product bias and enable cross-study comparisons. Ultimately, aligning study design with biological mechanisms and clinical indications through rational outcome selection will be essential to evaluate platelet derivatives as contemporary regenerative interventions with defined products, measurable quality, and clinically significant outcomes.